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Abstract
Background: The fear of hypoglycemia is the strongest barrier when patients with type 1 diabetes mellitus consider physical ac-
tivity. There is still a lack of information regarding pre- and post-exercise therapy adaptation strategies with respect to different
exercise intensities corresponding to the three phases of lactate metabolism.
Objectives: The aim of this experimental, cross-sectional study was to investigate exercise intensity-dependent, short-acting insulin
reductions to avoid hypoglycemia, applying standardized exercises using insulin degludec (®Tresiba/Novo Nordisk, Denmark).
Methods: Seven male participants with type 1 diabetes mellitus were switched to insulin degludec. Intensities for the 30 minutes
continuous cycle ergometer exercise tests were set at 5% below (A) and above (B) the lactate turn point 1, and below (C) and above
(D) the lactate turn point 2. Reductions in short-acting insulin were applied as following: by 25% for intensity A, by 50% for intensity
B and by 75% for intensities C and D four hours before the start of exercise and immediately after exercise. Blood glucose, interstitial
glucose, lactate, catecholamines, cortisol, IGF-1 and glucagon were measured.
Results: No hypoglycemic events occurred, but linear blood glucose decreases were observed: 2.01± 1.04 mmol.L-1, P = 0.35 (A), 3.00
± 1.54 mmol.L-1, P = 0.48 (B), 3.42± 2.34 mmol.L-1, P = 0.40 (C), and 3.70± 3.36 mmol.L-1, P = 0.12 (D). Adrenaline, noradrenaline and
IGF-1 (B, C, D, not A), dopamine (C, D, not A and B) and cortisol (A, C, D, not B) increased significantly from baseline, but not glucagon
(P > 0.05). Interstitial glucose showed no post-exercise hypoglycemia.
Conclusions: The applied therapy adaptation before and after exercises was adequate to avoid hypoglycemia while using an ultra-
long-acting insulin.
Keywords: Glycemia, Metabolism, Hormones
1. Background
In addition to standard insulin therapy, regular exer-
cise has been suggested to lead to positive effects in pa-
tients with diabetes by lowering the risk of cardiovascu-
lar diseases and early all-cause mortality (1). Furthermore,
it was recently shown that adopting a healthy lifestyle in
patients with type 1 diabetes mellitus led to an improve-
ment in body fat, body mass index (BMI) and lipid profiles
as well as in blood pressure (2). Despite this evidence, the
fear of hypoglycemia is the strongest barrier when these
patients consider physical activity (3). Exercise-induced
hypoglycemia occurs if insulin levels are not adequately
lowered before starting to exercise, resulting in an ele-
vated risk of a high glucose uptake rate into the tissue (4).
Three possible strategies have been identified to prevent
exercise-induced hypoglycemia in patients with type 1 di-
abetes: first, insulin reduction (short-acting insulin (5-7)
or insulin basal rate in pump therapy (8)), second, sup-
plementation with carbohydrates (9) and third, the com-
bination of insulin reduction and carbohydrate ingestion
(10). As people with type 1 diabetes mellitus often suf-
fer from weight gain (11), short-acting insulin reduction
strategies arise as beneficial for weight management (12).
In the last few years, a novel ultra-long-acting insulin has
been developed (insulin degludec (IDeg) (®Tresiba/ Novo
Nordisk, Bagsvaerd, Denmark)). A recent study has shown
that intensive insulin therapy with IDeg is related to less
frequent nocturnal hypoglycemic events (13), lower levels
and smaller day-to-day variability of fasting plasma glu-
cose (14) while implementing a lower daily insulin dose
(15). It also showed a comparable symptomatic and cog-
nitive response to artificially induced hypoglycemia (16)
Copyright © 2017, Sports Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0
International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the
original work is properly cited.
Moser O et al.
in comparison to insulin glargine (IGlar) (Lantus/ Sanofi-
Aventis, France). Only a few studies have investigated phys-
ical exercise in patients with type 1 diabetes when treated
with IDeg (17, 18). In a recent study (18), no hypoglycemic
events were reported during 30 minutes cycle ergometer
exercise at 65% peak oxygen uptake with either IDeg or
IGlar, but this study only investigated one single exercise
intensity. The incidence of late-onset hypoglycemia was
similar for both basal insulins indicating a similar risk of
hypoglycemia during and after exercise relative to other
long-acting insulins. There are currently no recommenda-
tions to counteract exercise-induced hypoglycemia when
using Ideg. Importantly, most studies investigating the
effects of exercise in patients with type 1 diabetes melli-
tus prescribed exercise intensities as percentages of maxi-
mal oxygen uptake (VO2max), maximal heart rate (HRmax) or
maximal power output (Pmax) (6, 19, 20), which results in in-
homogeneous metabolic and cardiorespiratory responses
as shown earlier (21, 22). IDeg has not yet proven to be effec-
tive in combination with different short-acting insulin re-
ductions at exercise intensities near to or above the anaero-
bic threshold. There is a lack of information regarding pre-
and post-exercise adaptation strategies for short-acting in-
sulin with respect to different exercise intensities corre-
sponding to the three phases of lactate metabolism. As a
hypothesis we expected that standardized therapy adapta-
tions are successful in avoiding hypoglycemia during and
after exercise in patients with type 1 diabetes mellitus.
2. Objectives
The main aim of the present study was, therefore, to
prove that standardized short-acting insulin dose reduc-
tions, dependent on specified exercise intensities, are suc-
cessful in avoiding hypoglycemia during and after exer-
cise. As a second aim, we assessed the acute metabolic, car-
diopulmonary, and hormonal responses at these exercise
intensities. A third aim was to extrapolate blood glucose
decreases during continuous exercise at different exercise
intensities to predict the maximal duration of exercise be-
fore hypoglycemia occurs.
3. Methods
3.1. Participants
To be eligible for the study, participants had to be
male with type 1 diabetes mellitus for a duration of at
least 12 months, aged 18 to 35 years, HbA1c below 8 % (64
mmol.mol-1), fasting c-peptide below 0.3 nmol.L-1, treated
with intensive insulin therapy, no disease-related long-
term complications and no other physical and/or mental
diseases. Just male participants were recruited since the fe-
male menstrual cycle influences glucose metabolism, and
could interfere with the long investigation period. Par-
ticipants were excluded if they had a history of any dis-
ease that could confound the results of the trial, use of
drugs (which may interfere with the interpretation of the
trial’s results or is known to be clinically relevant in inter-
fering with insulin action), recovery from hypoglycemia,
current alcohol addiction, controlled substance abuse (de-
termined by investigator questioning, documented in the
case report form (CRF)), known or suspected allergy to trial
products or related products, language barriers preclud-
ing adequate understanding, unwillingness, mental inca-
pacity, and any condition that the study physician feels
would interfere with the trial participation. Testing day
inclusion criteria were absence of hypoglycemia 48 hours
prior to testing, documented by the participant by self-
measured blood sugar and additionally controlled by the
observation of the continuous glucose monitoring system
(CGM) (®Guardian, REAL-Time System, Medtronic, Fridley,
Minnesota, USA) by the study physician, as well as no alco-
hol consumption 24 hours before testing determined by
questioning (documented in the CRF). Testing day exclu-
sion criteria were defined as: illness, glucose levels before
testing below 4.4 mmol.L-1, CGM problems, incorrect time
or amount of last short-acting insulin injection before test-
ing. All inclusion and exclusion criteria were reported in a
CRF. Hypoglycemia was set at≤ 3.9. mmol.L-1.
3.2. Measures
3.2.1. Preliminary Adjustment of Long-Acting Insulin Therapy
The usual long-acting insulin dose per day was deter-
mined by interviewing at the first visit four weeks prior
to the study. IDeg (®Tresiba/Novo Nordisk, Bagsvaerd,
Denmark) was subcutaneously injected once daily in the
evening, starting with a dose of 70% of total daily long-
acting insulin (16). In cases of hypo- or hyperglycemia, the
insulin dose was adjusted. A run-in period of one month
ensured an optimal long-acting insulin therapy.
3.3. Incremental Exercise Test
All participants performed an incremental cycle er-
gometer exercise test until exhaustion to determine ex-
ercise intensities for the subsequent continuous cycle er-
gometer exercise tests (21). At the beginning of the incre-
mental exercise test, participants passively sat on the er-
gometer (3 min - 0 W). Afterwards participants warmed-
up cycling for 3 minutes (40 W). Subsequently, the inten-
sity was increased every minute (20 W) until maximal ex-
haustion, followed by 3 minutes active recovery (40 W)
and 3 minutes passive recovery (0 W). The first (LTP1) and
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the second lactate turn point (LTP2) were identified by a
linear regression break point analysis (relationship of lac-
tate concentration to power output). According to the
three-phases of energy supply, LTP1 and LTP2 were deter-
mined as the intersection point between two regression
lines. The individual test results were used to define the
intensities for the continuous exercise tests for each pa-
tient. These workload intensities were set at 5% of Pmax
below and above LTP1 and LTP2 do define four metaboli-
cally different individual exercise intensities. Exercise in-
tensity below LTP1 (A) conformed to regular physical activ-
ity as well as occupational work for several hours, and ex-
ercise above LTP1 (B) conformed to moderate walking or
low-intensity running. The intensity just below LTP2 (C)
matched to high-intensity continuous running or cycling
in a metabolic steady state but for a limited duration, and
the intensity above LTP2 (D) corresponded to clearly lim-
ited exercise duration without a lactate steady state and
with early termination due to exhaustion.
3.4. Continuous Cycle Ergometer Exercise Tests
Each patient performed four 30 minutes continuous
cycle ergometer exercise tests (A, B, C, D). The four tests
were separated by one week for recovery. Exercise intensi-
ties were not randomized in order to minimize potential
risks, as the defined exercise intensities and short-acting
insulin reductions were used for the first time in that ex-
perimental setting. Since only one exercise test of 30 min-
utes was performed within one week, no “training effects”
were suggested, as no intra-individual differences were
observed during passive and active warm-up periods in
metabolic and cardiorespiratory responses. Tests begun
identically to the incremental exercise tests (passive and
active warm-up) followed by a stepwise increase of exer-
cise intensity (20 W.min-1) until the final target workload
for each subject was reached and maintained for 30 min-
utes. Finally, the cool-down period was similar to the in-
cremental exercise test (3 minutes active recovery at 40 W
and 3 minutes passive recovery at 0 W). The warm-up, the
incremental approach to the target workload and the re-
covery phase were performed in order to control for day-
to-day variability in physiological responses.
3.5. Analyses
Blood lactate and blood glucose concentrations were
determined by taking capillary blood samples (ear lobe)
during all tests at rest, warm-up, during exercise and recov-
ery; blood samples were analyzed by means of a enzymatic-
amperometric method (®Biosen S-line, EKF diagnostics,
Germany). Breath-by-breath data were collected continu-
ously during all tests, and 5 s average data were used for
analyses (ZAN 600, ZAN, Germany). Heart rate was mea-
sured beat-to-beat during all tests, and 5 s average data
were used for calculations (PE 4000, Polar Electro, Fin-
land). A 12-lead electrocardiogram and blood pressure
measurements (every 2 minutes) were used for cardiac
monitoring. Venous samples of catecholamines, cortisol,
insulin-like growth factor-1 (IGF-1), and glucagon were de-
termined from a cubital vein before the start of the exer-
cise, at 15 minutes during exercise, and at the end of each
continuous 30 minutes exercise test (A - D). Adrenaline
(limit of detection 10 pg.mL-1), noradrenaline (limit of de-
tection 50 pg.mlL-1), and dopamine (limit of detection 20
pg.mL-1) were quantified by ®RIA (DRG Diagnostics, USA).
Glucagon (limit of detection 20 pg.ml-1) was determined by
®RIA (ICN, USA), and cortisol (detection of 0.20 - 75µg.dL-1)
and IGF-1 (limit of detection 10.1 pg.mL-1) by ®CLIA (CEN-
TAUR, siemens healthcare diagnostics, USA). C-peptide was
measured by ®Advia Centaur (CENTAUR, siemens health-
care diagnostics, USA) (detection of 0.05 - 30 ng.mL-1).
3.6. Continuous Glucose Monitoring
Patients were fitted with a CGM and provided with
all necessary instructions. The CGM sensor was inserted
into the posterolateral abdominal region a minimum of
24 hours pre-exercise to measure blood glucose alongside
self-measurement to avoid hypoglycemic events. The CGM
was left inserted for another 24 hours post-exercise to ob-
serve glucose activity and the effect of exercise intensity (A,
B, C, D). CGM alerts were set at below 4.4 mmol.L-1 and above
16.0 mmol.L-1 during the two 24 hours periods. The study
physician asked about previous hypoglycemic events be-
fore the exercise tests, and any relevant information was
documented in a CRF.
3.6.1. Short-Acting Insulin Reduction
After an overnight fast, each participant received a
standardized meal (last meal before exercise testing) on
test days (Fortimel Extra, Nutricia GmbH, Germany). The
carbohydrate amount of 59±8 g before to the tests was cal-
culated on the mean amount at breakfast over the last four
weeks prior the study. Standardized nutrition was com-
posed of 39% carbohydrates, 36% proteins and 25% fat (For-
timel Extra, Nutricia GmbH, Germany). This standardized
meal and the before mentioned short-acting insulin injec-
tions were administered four hours before the start of the
exercise tests. This long time span was mainly applied to
see the exercise-induced blood glucose decrease by mini-
mizing the influence of short-acting insulin action during
cycling. The short-acting insulin dose was reduced by 40%
for the incremental exercise test, by 25% for exercise A, by
50% for exercise B and by 75% for both exercise intensities C
and D, modified from Rabasa-Lhoret et al. (6). Post-exercise,
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patients injected the same reduced short-acting insulin
dose and ingested the same amount of carbohydrate as be-
fore testing to simulate post-exercise eating habits. For the
rest of the day, patients were requested to continue with
their regular insulin dose according to the formula (carbo-
hydrate factor = (5.7 * bodyweight (kg)) / total daily insulin
dose-1).
3.7. Procedures
All participants gave a signed informed consent prior
the trial started. The trial was approval by the local ethics
committee, according to good clinical practice (GCP) and
declaration of Helsinki (DoH) as well as approved by Clin-
cicaltrials.gov. The study consisted of 20 visits at the outpa-
tient clinic of Endocrinology and Metabolism, and at the
exercise physiology laboratory. The outpatient clinic was
visited for the adjustment to IDeg (visits 1 - 10, with three
days in between) and to equip participants with CGM (vis-
its 12, 14, 16, and 18, with one week in between). The exer-
cise physiology laboratory was visited for the incremental
exercise test (visit 11) and for the continuous cycle ergome-
ter exercise tests (visits 13, 15, 17, and 19, with one week in
between).
3.8. Statistical Analysis
A repeated-measures ANOVA design was calculated
with an effect size of 0.5 and an α-error of 0.05 based on
a pilot study with a main outcome defined as the expected
blood glucose decrease. With a sample size of six patients
with type 1 diabetes mellitus the power (β-1) is greater than
0.95. To control for dropout, we conducted our study with
seven participants. Data were normally distributed ex-
cept CGM levels, analyzed via Shapiro-Wilk normality test.
Participants’ anthropometric data, performance charac-
teristics and diabetes specific data are given as mean and
range. Means of blood glucose decrease and hormone re-
sponses during exercise were calculated by repeated mea-
sures ANOVA and Tukey’s multiple comparison post-hoc
test. Blood glucose decrease was extrapolated from the end
of the test until reaching a hypoglycemic threshold of 3.9
mmol.L-1. Relationships between blood glucose decreases
and carbohydrate oxidation were performed by Pearson’s
correlation coefficient analysis. CGM data are given as me-
dian and range (upper limit - lower limit), and coefficient
of variation (CV) analysis from median was applied. For
analysis of time spent in hyper- or hypoglycemia with the
CGM we used the median and range for the values above
10.0 mmol.L-1 or below 3.9 mmol.L-1. All statistics were cal-
culated with prism Software version 4.0 (GraphPad, USA).
4. Results
Seven men with type 1 diabetes mellitus were enrolled
in this study (Table 1). All participants were switched to
ultra-long-acting IDeg with an average dose of 68 ± 13%
of their usual pre-study long-acting insulin dose, for daily
conditions. All data were normally distributed.
Average oxygen consumption for each exercise inten-
sity was 36± 10% VO2max (A), 40± 13% VO2max (B), 78± 11%
VO2max (C), and 84± 15% VO2max (D).
Blood lactate concentration profiles corresponded
well to the expected patterns with resting lactate levels in
A, slightly but significantly elevated steady state lactate lev-
els in B, significantly elevated but still steady state lactate
levels in C, but no steady state and a continuous increase
of lactate with an early termination of exercise in D (Figure
1A).
The average short-acting insulin dose four hours be-
fore the exercise on each test day was 0.041± 0.014 U.kg-1
for the incremental exercise test, 0.054 ± 0.014 U.kg-1 for
continuous cycle ergometer exercise A, 0.027±0.014 U.kg-1
for B, and 0.014 ± 0.007 U.kg-1 for C and D, respectively.
Those amounts were combined with a carbohydrate meal
of 0.797±0.069 g.kg-1 (Fortimel Extra, Nutricia GmbH, Ger-
many), which was the average amount ingested at break-
fasts 4 weeks prior to the study start.
4.1. Blood Glucose Levels and Carbohydrate Oxidation
No participant experienced hypoglycemia (blood glu-
cose≤ 3.9 mmol.l-1), neither during exercise nor within 24
hours after any of the 35 exercise sessions. All participants
maintained a glucose steady state during the incremen-
tal exercise test when short-acting insulin was reduced by
40%, with no difference between the start and the end of
the test (10.58± 3.42 mmol.L-1 vs. (10.24± 3.48 mmol.L-1, P
= 0.85). Starting blood glucose for the continuous cycle er-
gometer exercise tests were found at 10.42± 2.01 mmol.L-1
(range: 6.19 - 12.31 mmol.L-1) for exercise intensity A, 12.78
± 3.76 mmol.L-1 (range: 7.44 - 16.01 mmol.L-1) (B), 12.84 ±
3.21 mmol.L-1 (range: 6.15 - 16.40 mmol.L-1) (C), and 14.98±
2.43 mmol.L-1 (range: 9.72 - 16.16 mmol.L-1) (D) (Figure 2).
Blood glucose linearly decreased in all continuous exercise
sessions with delta values of 2.01± 1.04 mmol.L-1, P = 0.35
(A), 3.00 ± 1.54 mmol.l-1, P = 0.48 (B) 3.42 ± 2.34 mmol.l-
1, P = 0.40 (C), and 3.70 ± 3.36 mmol.L-1, P = 0.12 (D), re-
spectively. Delta blood glucose was not significantly differ-
ent (P = 0.64) and not significantly correlated with carbo-
hydrate oxidation (r = 0.31; P = 0.34). Carbohydrate oxida-
tion, which was calculated from respiratory data, was 1.08
± 0.39 g.min-1 for A, 1.28 ± 0.42 g.min-1 for B, 3.07 ± 0.44
g.min-1 for C, and 4.02 ± 0.44 g.min-1 for D (Figure 1B). A
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Table 1. Participants’ Characteristics, Performance Characteristics, and Diabetes Specific Dataa
Variable Characteristic Characteristic Characteristic
Participants’ characteristics
Age, y Height, m Body weight, kg BMI, kg/m2
24.7 (20 - 34) 1.76 (171 - 181) 74 (66 - 81) 23.9 (20 - 27)
Performance characteristics
VO2max, ml.kg-1 .min-1 PLTP1 , W PLTP2 , W Pmax , W
52 (41 - 67) 82.1 (51 - 111) 192.1 (151 - 253) 284.3 (230 - 360)
Diabetes specific data
Hba1c, No.%, mmol.mol-1 c-peptide, nmol.L-1 Diabetes, y CHO factor, g
7.4 (57) ((6.5 - 8) (47 - 64)) 0.13 (0 - 0.3) 16.9 (4 - 26) 12 (9 - 16)
Abbreviations: VO2max , maximal oxygen uptake; PLTP1 , Power at the first lactate turn point; PLTP2 , Power at the second lactate turn point; Pmax , maximal power output;
CHO, carbohydrate.
aValue are expressed as Mean± SD.
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linear extrapolation of blood glucose decrease to the hypo-
glycemic threshold of 3.9 mmol.L-1 was significantly differ-
ent only between exercise intensity A and C (P = 0.03). The
durations to the hypoglycemic threshold were found at 120
± 56 minutes (A), 92± 47 minutes (B), 80± 62 minutes (C)
and 59± 52 minutes (D) (Figure 2).
4.2. Late Glycemic Onset Measured by CGM
Median (range) glucose levels during 24 hours post ex-
ercise were 8.52 (4.99 - 12.30) mmol.L-1 with a coefficient of
variation (CV) of 16.49% (A), 9.86 (5.96 - 15.67) mmol.L-1, CV
18.04% (B), 8.98 (5.91 - 13.57) mmol.L-1, CV 24.90% (C), and
8.48 (5.57 - 13.36) mmol.L-1, CV 28.15% (D). No hypoglycemia
(≤ 3.9 mmol.L-1) was found for all exercise intensities dur-
ing the 24 hours post-exercise period. Hyperglycemic con-
ditions (> 10.0 mmol.L-1) were observed in A for 280 min-
utes with an average of 10.6 (10 - 12.1) mmol.L-1, in B for 660
minutes with 10.9 (10 - 14.5) mmol.L-1, in C for 415 minutes
with 11.5 (10 - 14.7) mmol.L-1, and in D for 340 minutes with
11.8 (10 - 15.9) mmol.L-1 (Figure 3).
4.3. Hormone Levels
Adrenaline (C and D, P < 0.01), noradrenaline (B, C and
D, P < 0.01), dopamine (C and D, P < 0.01), cortisol (A, P =
0.03; C, P = 0.01 and D, P = 0.03), and IGF-1 (B, P = 0.04; C and
D, P < 0.01) but not glucagon (P > 0.05), significantly in-
creased during constant load exercise (Figure 4). The time
course of adrenaline, noradrenaline, and cortisol was sim-
ilar to the pattern of blood lactate concentrations. This
clearly displayed the expected three phase time course for
these variables with no increase for intensities A and B, but
Asian J Sports Med. 2017; 8(1):e42160. 5
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Figure 2. Exercise-Intensity Dependent Linear Blood Glucose Decrease During Continuous Exercise Tests (A Represents Exercise Intensity A, B Represents Exercise Intensity
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a significant increase in C, and a marked elevation and no
steady state in D.
5. Discussion
Our study included low and high exercise intensities at
5% of Pmax below and above both lactate turn points. Even
for high intensity exercise (C and D), the applied short-
acting insulin reductions in combination with IDeg were
found to be safe. This is highly relevant since many patients
with type 1 diabetes mellitus are performing high-intensity
competitive sports (23). In comparison to the findings of
Heise and colleagues (18), where exercise intensity was set
at 65 % of VO2max with the same duration as in our study (30
minutes), the observed blood glucose decrease was higher
in our study. Due to different exercise prescription meth-
ods and differences in exercise intensities, a comparison of
these results is difficult. Our study showed a dose-response
relationship of exercise intensity and the decrease of blood
glucose concentration during continuous cycle ergometer
exercises independent of insulin reduction. The blood glu-
cose decrease was linear with time and was dependent on
exercise intensity, which allows to estimate critical time
limits (time to reach the hypoglycemic threshold of 3.9
mmol.L-1) as well as to prospectively calculate the risk of
hypoglycemia. The linear extrapolation of the blood glu-
cose decrease during exercises A, B, C, and D showed an
intensity-related range of duration between 120± 56 min-
utes (A) and 59±52 minutes (D) to reach the hypoglycemic
threshold. A prospective calculation of the expected blood
glucose decrease might be a simple method which could
be used easily by the patients themselves, and which could
help patients learn when and how to supplement carbohy-
drates with respect to exercise intensity and duration. For
conclusive recommendations, however, additional large-
scale studies are required specifically on the influence of
the pre-exercise glucose concentration. Since we started
at high blood glucose levels in our tests, it has to be criti-
cally mentioned that these conditions (although usual in
daily practice) (23) might influence the glucose consump-
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tion rate and the glucose decrease with time as shown
by Jenny and colleagues (24). These authors (24) demon-
strated that in hyperglycemic conditions, metabolism was
dominated by carbohydrate oxidation. Furthermore, hy-
perinsulinemic conditions were shown to directly increase
exogenous glucose utilization (25). Based on these stud-
ies, we assume that the hyperglycemic pre-exercise blood
glucose levels in our study subsequently influenced the
blood glucose decreases during exercise. On the other
hand, it was shown by Stettler and colleagues (26) that hy-
perglycemia did not affect exercise capacity, and no sig-
nificant differences were found in cardiorespiratory and
metabolic responses when hyper- and euglycemic condi-
tions were compared. Previous self-reported glucose lev-
els before an exercise in athletes with type 1 diabetes mel-
litus (23), were similar to our pre-exercise values. These
results indicate that high blood glucose levels illustrate
real-life situations in patients with type 1 diabetes melli-
tus performing regular exercise. On the other hand, the
starting blood glucose level at exercise intensity D was non-
physiologically high, but was suggested necessary to avoid
hypoglycemia during and after high-intensity anaerobic
exercise without any supplementation of carbohydrates
during the test. As the accelerated lactate accumulation
and acidosis of this exercise test clearly limits the dura-
tion, there is no need to adapt to artificially high start-
ing glucose concentrations even if a high-intensity interval
method is applied (17). While most of our post-exercise val-
ues for time spent in hyperglycemia (> 10.0 mmol.L-1) were
comparable to a recent study with similar conditions (7),
we identified a long-time period of 660 minutes of hyper-
glycemia at exercise intensity B. This might be explained by
an inadequate and exaggerated short-acting insulin reduc-
tion after exercise. The 50 % reduction of insulin seems to
be too high for people with type 1 diabetes mellitus for this
type of exercise. Unfortunately, due to the low number of
available studies, recommendations for individual insulin
reductions for exercise are usually too generalized for pa-
tients with type 1 diabetes mellitus. One main outcome
of our study was to show that the individual turn points
of lactate (LTP1, LTP2) from an incremental exercise test, al-
low to clearly describe three different exercise domains in-
dicated by a distinct difference of blood lactate and cat-
echolamine responses. This is in contrast to most stud-
ies, which used exercise intensity prescriptions by means
of percentages of maximal values (e.g. VO2max or maxi-
mal heart rate). It was shown by Scharhag-Rosenberger
and colleagues (22) that this kind of exercise intensity pre-
scription for endurance training and study purposes gave
a non-acceptable range of metabolic responses that may
be individually inadequate and inhomogeneous within a
group of subjects. Therefore, these authors (22) as well as
others (21, 27) recommended using exercise intensity pre-
scriptions based on thresholds (turn points) but not on %
of VO2max or HRmax. Applying the individual lactate turn
point method to determine individual exercise intensities
resulted in the expected exercise intensity-dependent re-
sponse pattern for lactate, adrenaline, noradrenaline, cor-
tisol, IGF-1, and dopamine. A lack of a glucagon response in
patients with a long duration of type 1 diabetes, has been
shown to be tightly linked to endogenous insulin defi-
ciency (28), specific beta-cell and neural factors. One short-
coming of the study was that we did not measure insulin
levels and just controlled the injected insulin doses and c-
peptide levels. Therefore, we could not directly analyze the
effect of insulin on the decrease of blood glucose. The fairly
high standard deviation of the blood glucose decrease and
the difference in starting blood glucose levels, despite the
same short-acting insulin reduction (for exercise intensi-
ties C and D), could be considered normal when analyz-
ing the patients’ intra-variability in insulin action (29, 30).
Our study was also limited by the low number of subjects
and the short duration of exercise bouts (30 minutes). A
longer duration may be necessary for lower exercise in-
tensities (A, B) to better validate the extrapolation model.
As we just used the recommended intensity-dependent in-
sulin reduction strategy with standardized exercise con-
ditions, further studies are necessary to investigate differ-
ent reduction strategies for short-acting insulin related to
our theory-based exercise prescription model, including
a greater number of subjects. Despite these limitations,
our study was able to show that individual recommenda-
tions for the reduction of short-term insulin are possible
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Figure 4. Comparison of Adrenaline (A), Noradrenaline (B), Dopamine (C), Cortisol (D), Glucagon, (E) and IGF-1 (F) With Respect to the Four Different Exercise Intensities, Given
as Mean± SD. Solid Line For Exercise Intensity A, Broken Line For B, Dotted Line for C, and Dash-Dot Line For D
and safe if applied to individually defined exercise intensi-
ties. The method of our study allows to identify the individ-
ual exercise intensity-dependent, maximal duration, be-
fore reaching the hypoglycaemia threshold during a con-
stant load exercise with a given insulin reduction strategy,
instead of an overall recommendation.
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